See today's BioWorld Asia
To read the full story, subscribe or sign in.

Henlius bevacizumab biosimilar receives China marketing approval

Dec. 14, 2021
By Doris Yu
Shanghai Henlius Biotech Inc.’s self-developed Hanbeitai (bevacizumab biosimilar) has received marketing approval from China’s NMPA.
BioWorld Asia Regulatory Cancer Biosimilar China NMPA